tirzepatide for cardiovascular disease Bridging the gap between GLP1-receptor agonists and outcomes: evidence the role of | Cardiovascular Diabetology Mounjaro, Zepbound Lowers Risk of

While earlier research established that GLP-1s suppress appetite and promote weight loss, little was known about their influence on specific food categories and overall dietary behavior

Because the Tmax window is broader (8 to 72 hours), there is less precision in predicting exactly when peak effects will hit on any given week

Clinical trials consistently demonstrate that once-weekly TZP leads to substantial and sustained reductions in body weight often exceeding 15%20% and marked improvements in glycaemic control, with reductions in HbA1c surpassing many existing therapies

GLP-1 agonists have become popular treatments for weight loss and type 2 diabetes, and newer studies suggest other health benefits as well